PTPA and cancer: Protein phosphatase 2A (PP2A) inhibition drives resistance to several kinase inhibitors in multiple cancer types, therefore PP2A reactivation could be envisioned as a novel therapeutic opportunity to overcome kinase inhibitor resistance6–9.